Baseline severity of sepsis in subjects of the prowess and the Kybersept clinical trials on endogenous anticoagulants.
Wiedermann
Christian J
CJ
Department of Internal Medicine, Central Hospital of Bolzano, Bolzano (BZ), Italy. Christian.Wiedermann@asbz.i
Keinecke
Heinz-Otto
HO
Jürs
Mathias
M
Opal
Steve M
SM
D000925:Anticoagulants / Q000008:administration & dosage*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D011486:Protein C / Q000008:administration & dosage*; D011994:Recombinant Proteins / Q000008:administration & dosage*; D018805:Sepsis / Q000188:drug therapy* / Q000401:mortality*; D012720:Severity of Illness Index; D015996:Survival Rate
D000925:Anticoagulants; D011486:Protein C; D011994:Recombinant Proteins